Tettero JM, Ngai LL, Bachas C, Breems DA, Fischer T, Gjertsen BT, Gradowska P, Griskevicius L, Janssen JJ, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Valk PJ, Löwenberg B, Ossenkoppele GJ, Cloos J. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival. Haematologica 2023;108(10):2794-2798; https://doi.org/10.3324/haematol.2022.282639.